A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia

References

• Thieblemont C, Molina T, Davi F. Optimizing therapy for nodal marginal zone lymphoma. Blood. 2016;127(17):2064–2071.
   PubMed Web of Science ®Google Scholar
• Yun S, Johnson AC, Okolo ON, et al. Waldenström macroglobulinemia: review of pathogenesis and management. Clin Lymphoma Myeloma Leuk. 2017;17(5):252–262.
   PubMed Web of Science ®Google Scholar
• Maddocks K. Update on mantle cell lymphoma. Blood. 2018;132(16):1647–1656.
   PubMed Web of Science ®Google Scholar
• Denlinger NM, Epperla N, William BM. Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. Cancer Manag Res. 2018;10:615–624.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Treon SP. Management of Waldenström macroglobulinemia in 2020. Hematology Am Soc Hematol Educ Program. 2020;2020(1):372–379.
   PubMedGoogle Scholar
• de Claro RA, McGinn KM, Verdun N, et al. FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin Cancer Res. 2015;21(16):3586–3590.
   PubMed Web of Science ®Google Scholar
• Raedler LA. Imbruvica (ibrutinib): first drug approved for the treatment of patients with waldenström's macroglobulinemia. Am Health Drug Benefits. 2016;9(Spec Feature):89–92.
   PubMedGoogle Scholar
• Dreyling M, Campo E, Hermine O, ESMO Guidelines Committee, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv62–iv71.
   PubMedGoogle Scholar
• Kastritis E, Leblond V, Dimopoulos MA, ESMO Guidelines Committee, et al. Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv41–iv50.
   PubMed Web of Science ®Google Scholar
• Kumar A, Sha F, Toure A, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 2019; 9(6):50.
   PubMed Web of Science ®Google Scholar
• Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–745.
   PubMed Web of Science ®Google Scholar
• Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129(16):2224–2232.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Chihara D, Romaguera JE, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26(6):1175–1179.
   PubMed Web of Science ®Google Scholar
• Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559–1563.
   PubMed Web of Science ®Google Scholar
• Apostolidis J, Sayyed A, Darweesh M, et al. Current clinical applications and future perspectives of immune checkpoint inhibitors in non-Hodgkin lymphoma. J Immunol Res. 2020;2020:9350272.
   PubMed Web of Science ®Google Scholar
• Tobinai K, Klein C, Oya N, et al. A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther. 2017;34(2):324–356.
   PubMed Web of Science ®Google Scholar
• Moynihan KD, Irvine DJ. Roles for innate immunity in combination immunotherapies. Cancer Res. 2017;77(19):5215–5221.
   PubMed Web of Science ®Google Scholar
• Palomba ML, Till BG, Park SI, et al. A phase IB study evaluating the safety and clinical activity of atezolizumab combined with obinutuzumab in patients with relapsed or refractory non‐Hodgkin lymphoma (nhl). Hematol Oncol. 2017;35:137–138.
   Google Scholar
• Herold M, Hoster E, Janssens A, et al. Immunochemotherapy with obinutuzumab or rituximab in a subset of patients in the randomised GALLIUM trial with previously untreated marginal zone lymphoma (MZL). Hematol Oncol. 2017;35(S2):146–147.
   Google Scholar
• Cheson BD, Pfistner B, Juweid ME, International Harmonization Project on Lymphoma, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
   PubMed Web of Science ®Google Scholar
• Owen RG, Kyle RA, Stone MJ, et al.; VIth International Workshop on Waldenström macroglobulinaemia. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013;160(2):171–176.
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Gaulard P, Lavergne-Slove A, et al. Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma. Gut. 2003;52(11):1656
   PubMed Web of Science ®Google Scholar
• Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22(3):487–495.
   PubMed Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–346.
   PubMedGoogle Scholar
• Scott DW, Abrisqueta P, Wright GW, for the Lymphoma/Leukemia Molecular Profiling Project, et al. New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies. J Clin Oncol. 2017;35(15):1668–1677.
   PubMed Web of Science ®Google Scholar
• Till BG, Park SI, Popplewell LL, et al. Safety and clinical activity of atezolizumab (anti-PDL1) in combination with obinutuzumab in patients with relapsed or refractory non-Hodgkin lymphoma [abstract]. Blood. 2015; 126(23):5104–5104.
   Web of Science ®Google Scholar
• Noy A, de Vos S, Coleman M, et al. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv. 2020;4(22):5773–5784.
   PubMed Web of Science ®Google Scholar
• Becnel MR, Nastoupil LJ, Samaniego F, et al. Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. 2019;185(5):874–882.
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: analysis of the surveillance, epidemiology, and end results database. Cancer. 2013;119(3):629–638.
   PubMed Web of Science ®Google Scholar
• Kalpadakis C, Pangalis GA, Sachanas S, et al. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. Blood. 2018;132(6):666–670.
   PubMed Web of Science ®Google Scholar
• Zucca E, Conconi A, Martinelli G, et al. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017;35(17):1905–1912.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med. 2015;372(15):1430–1440.
   PubMed Web of Science ®Google Scholar
• Rule S, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia. 2018;32(8):1799–1803.
   PubMed Web of Science ®Google Scholar
• Shi Y, Deng L, Song Y, et al. CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in chinese diffuse large B-cell lymphoma patients. Int J Hematol. 2018;108(3):254–266.
   PubMed Web of Science ®Google Scholar
• Alonso-Alvarez S, Vidriales MB, Caballero MD, et al. The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy. Leuk Lymphoma. 2017; 58(5):1144–1152.
   PubMed Web of Science ®Google Scholar